Search research articles
Contact Us
Filters
Showing results (71-80 of 153) with videos related to
Page
of 16
Sort By:
Haematologica
|
February 18, 2014
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
Timothy P Hughes, Andreas Hochhaus, Hagop M Kantarjian, et al.
Oncotarget
|
March 17, 2016
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients
Simona Soverini, Caterina De Benedittis, Katerina Machova Polakova, et al.
Haematologica
|
March 7, 2007
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
Simona Soverini, Sabrina Colarossi, Alessandra Gnani, et al.
Oncotarget
|
May 24, 2017
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells
Simona Salati, Valentina Salvestrini, Chiara Carretta, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 25, 2024
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network
Massimo Breccia, Rosalba Cucci, Giovanni Marsili, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 4, 2009
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response
Francesca Palandri, Ilaria Iacobucci, Simona Soverini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 20, 2006
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment
Ilaria Iacobucci, Gianantonio Rosti, Marilina Amabile, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 2008
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML
Francesca Palandri, Ilaria Iacobucci, Giovanni Martinelli, et al.
Annals of Hematology
|
October 12, 2012
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia
Mario Tiribelli, Roberto Latagliata, Luigiana Luciano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 26, 2006
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia
Simona Soverini, Sabrina Colarossi, Alessandra Gnani, et al.
Page
of 16
Search research articles
Search
Showing results (71-80 of 153) with videos related to
Sort By:
Page
of 16
Haematologica
|
February 18, 2014
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
Timothy P Hughes, Andreas Hochhaus, Hagop M Kantarjian, et al.
Oncotarget
|
March 17, 2016
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients
Simona Soverini, Caterina De Benedittis, Katerina Machova Polakova, et al.
Haematologica
|
March 7, 2007
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
Simona Soverini, Sabrina Colarossi, Alessandra Gnani, et al.
Oncotarget
|
May 24, 2017
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells
Simona Salati, Valentina Salvestrini, Chiara Carretta, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 25, 2024
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network
Massimo Breccia, Rosalba Cucci, Giovanni Marsili, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 4, 2009
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response
Francesca Palandri, Ilaria Iacobucci, Simona Soverini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 20, 2006
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment
Ilaria Iacobucci, Gianantonio Rosti, Marilina Amabile, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 2008
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML
Francesca Palandri, Ilaria Iacobucci, Giovanni Martinelli, et al.
Annals of Hematology
|
October 12, 2012
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia
Mario Tiribelli, Roberto Latagliata, Luigiana Luciano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 26, 2006
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia
Simona Soverini, Sabrina Colarossi, Alessandra Gnani, et al.
Page
of 16